Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours

AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumours who have ...

Related Keywords

United Kingdom ,Japan ,Cambridge ,Cambridgeshire ,United States ,America ,Trastuzumab Deruxtecan ,Susan Galbraith ,Daiichi Sankyo Enhertu ,Ken Takeshita ,Daiichi Sankyo ,Investor Relations Team ,European Society For Medical Oncology Congress ,Astrazeneca ,Nasdaq ,Drug Administration ,Lung Cancer Mutation Consortium ,National Cancer Institute ,Company On Social Media ,Daiichi Sankyo Company ,Time Oncology Review ,Biologics License Application ,Priority Review ,Prescription Drug User Fee Act ,Executive Vice President ,Global Head ,Real Time Oncology Review ,Project Orbis ,Medical Oncology Congress ,Breakthrough Therapy Designation ,Sankyo Company ,Rare Diseases ,Social Media ,Accessed January ,Patients With ,Expressing Solid Tumors ,Primary Results From ,Epidermal Growth Factor Receptor ,Mol Biol ,Lung Cancer Mutation ,Enhertu Marks First Targeted Therapy ,Mutant Lung ,Human Epidermal Growth Factor Receptor ,Cancer Metastasis ,